These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35691448)

  • 21. One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial.
    Singh AK; Gomez-Suescun JA; Stephans KL; Bogart JA; Hermann GM; Tian L; Groman A; Videtic GM
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):752-759. PubMed ID: 31445956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).
    Elamin YY; Gomez DR; Antonoff MB; Robichaux JP; Tran H; Shorter MK; Bohac JM; Negrao MV; Le X; Rinsurogkawong W; Lewis J; Lacerda L; Roarty EB; Swisher SG; Roth JA; Zhang J; Papadimitrakopoulou V; Heymach JV
    Clin Lung Cancer; 2019 Jan; 20(1):43-47. PubMed ID: 30343004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changing equipoise in the landscape of radiation for oligometastatic lung cancer.
    Schroeder SR; Leenders M; Iyengar P; de Ruysscher D
    Transl Lung Cancer Res; 2019 Sep; 8(Suppl 2):S184-S191. PubMed ID: 31673523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
    Hannan R; Christensen M; Christie A; Garant A; Pedrosa I; Robles L; Mannala S; Wang C; Hammers H; Arafat W; Courtney K; Bowman IA; Sher D; Ahn C; Cole S; Choy H; Timmerman R; Brugarolas J
    Eur Urol Oncol; 2022 Dec; 5(6):695-703. PubMed ID: 35985982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450).
    De Ruysscher D; Wanders R; Hendriks LE; van Baardwijk A; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Dingemans AC
    J Thorac Oncol; 2018 Dec; 13(12):1958-1961. PubMed ID: 30253974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Contemporary Update on the Role of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases in the Evolving Landscape of Oligometastatic Disease Management.
    Robin TP; Raben D; Schefter TE
    Semin Radiat Oncol; 2018 Oct; 28(4):288-294. PubMed ID: 30309639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer.
    Tibdewal A; Agarwal J; Mummudi N; Noronha V; Prabhash K; Patil V; Purandare N; Janu A; Kaushal R; Kannan S
    BMJ Open; 2021 Feb; 11(2):e041345. PubMed ID: 33589450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
    Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
    Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma.
    Liu Q; Zhu Z; Chen Y; Deng J; Ai D; Liu Q; Wang S; Wu S; Chen J; Zhao K
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):707-715. PubMed ID: 32417405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study.
    Zhang JT; Liu SY; Yan HH; Wu YL; Nie Q; Zhong WZ
    BMC Cancer; 2019 Nov; 19(1):1051. PubMed ID: 31694572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients.
    Hu F; Li C; Xu J; Guo J; Shen Y; Nie W; Zheng X; Wang L; Zhang H; Han B; Zhang X
    Lung Cancer; 2019 Sep; 135():138-144. PubMed ID: 31446986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial.
    Ludmir EB; Sherry AD; Fellman BM; Liu S; Bathala T; Haymaker C; Medina-Rosales MN; Reuben A; Holliday EB; Smith GL; Noticewala SS; Nicholas S; Price TR; Martin-Paulpeter RM; Perles LA; Lee SS; Lee MS; Smaglo BG; Huey RW; Willis J; Zhao D; Cohen L; Taniguchi CM; Koay EJ; Katz MHG; Wolff RA; Das P; Pant S; Koong AC; Tang C
    J Clin Oncol; 2024 Aug; ():JCO2400081. PubMed ID: 39102622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging Paradigm of Consolidative Thoracic Radiotherapy in Oligometastatic NSCLC.
    Gomez DR; Yang TJ; Tsai CJ
    Semin Radiat Oncol; 2021 Apr; 31(2):120-123. PubMed ID: 33610268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
    Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
    BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
    Tsai CJ; Yang JT; Shaverdian N; Patel J; Shepherd AF; Eng J; Guttmann D; Yeh R; Gelblum DY; Namakydoust A; Preeshagul I; Modi S; Seidman A; Traina T; Drullinsky P; Flynn J; Zhang Z; Rimner A; Gillespie EF; Gomez DR; Lee NY; Berger M; Robson ME; Reis-Filho JS; Riaz N; Rudin CM; Powell SN;
    Lancet; 2024 Jan; 403(10422):171-182. PubMed ID: 38104577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial.
    Liu Q; Chen J; Lin Y; Ye J; Shen W; Luo H; Li B; Huang W; Wei S; Song J; Wang Y; Yang H; Lai S; Zhu H; Ai D; Chen Y; Deng J; Hao S; Zhao K
    Lancet Gastroenterol Hepatol; 2024 Jan; 9(1):45-55. PubMed ID: 37980921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consolidative Radiotherapy in Oligometastatic Lung Cancer: Patient Selection With a Prediction Nomogram.
    Friedes C; Mai N; Hazell S; Fu W; Han P; Bowers M; Levy B; Forde PM; Voong R; Hales RK
    Clin Lung Cancer; 2020 Nov; 21(6):e622-e632. PubMed ID: 32624411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.
    No HJ; Raja N; Von Eyben R; Das M; Roy M; Myall N; Neal J; Wakelee H; Chin A; Diehn M; Loo BW; Chang DT; Pollom EL; Vitzthum LK
    Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):603-610. PubMed ID: 35654305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial.
    Xing L; Wu G; Wang L; Li J; Wang J; Yuan Z; Chen M; Xu Y; Fu X; Zhu Z; Lu Y; Han C; Xia T; Xie C; Li G; Ma S; Lu B; Lin Q; Zhu G; Qu B; Zhu W; Yu J
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1349-1358. PubMed ID: 33220395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.